Abeona Therapeutics Valuation
| ABEO Stock | USD 5.33 0.17 3.09% |
At this time, the firm appears to be overvalued. Abeona Therapeutics shows a prevailing Real Value of $4.76 per share. The current price of the firm is $5.33. Our model approximates the value of Abeona Therapeutics from analyzing the firm fundamentals such as return on equity of -2.1, and Current Valuation of 145.11 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Abeona Therapeutics' valuation include:
Price Book 5.0619 | Enterprise Value | Enterprise Value Ebitda (0.58) | Price Sales 61.6302 | Enterprise Value Revenue 53.2941 |
Overvalued
Today
Please note that Abeona Therapeutics' price fluctuation is slightly risky at this time. Calculation of the real value of Abeona Therapeutics is based on 3 months time horizon. Increasing Abeona Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Abeona Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Abeona Stock. However, Abeona Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.33 | Real 4.76 | Target 15.9 | Hype 5.33 | Naive 5.21 |
The intrinsic value of Abeona Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Abeona Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Abeona Therapeutics helps investors to forecast how Abeona stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Abeona Therapeutics more accurately as focusing exclusively on Abeona Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Abeona Therapeutics' intrinsic value based on its ongoing forecasts of Abeona Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Abeona Therapeutics' closest peers.
Abeona Therapeutics Cash |
|
Abeona Valuation Trend
Knowing Abeona Therapeutics' actual value is paramount for traders when making sound investment determinations. Using both Abeona Therapeutics' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Abeona Revenue by Product
Abeona Therapeutics Total Value Analysis
Abeona Therapeutics is presently forecasted to have valuation of 145.11 M with market capitalization of 232.35 M, debt of 5.4 M, and cash on hands of 20.1 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Abeona Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
145.11 M | 232.35 M | 5.4 M | 20.1 M |
Abeona Therapeutics Investor Information
About 76.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 2.05. Abeona Therapeutics had not issued any dividends in recent years. The entity had 1:25 split on the 5th of July 2022. Based on the key indicators related to Abeona Therapeutics' liquidity, profitability, solvency, and operating efficiency, Abeona Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Abeona Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Abeona Therapeutics has an asset utilization ratio of 5.47 percent. This suggests that the Company is making $0.0547 for each dollar of assets. An increasing asset utilization means that Abeona Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Abeona Therapeutics Ownership Allocation
Abeona Therapeutics holds a total of 43.59 Million outstanding shares. The majority of Abeona Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Abeona Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Abeona Therapeutics. Please pay attention to any change in the institutional holdings of Abeona Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Abeona Therapeutics Profitability Analysis
The company reported the previous year's revenue of 3.5 M. Net Loss for the year was (54.19 M) with loss before overhead, payroll, taxes, and interest of (31.4 M).About Abeona Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Abeona Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Abeona Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Abeona Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Abeona Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Abeona Therapeutics. We calculate exposure to Abeona Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Abeona Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 1.7 M | 1.6 M | |
| Pretax Profit Margin | (13.93) | (14.63) | |
| Operating Profit Margin | (12.12) | (12.73) | |
| Net Loss | (13.93) | (14.63) | |
| Gross Profit Margin | 0.49 | 0.51 |
Abeona Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 21.4 M |
Abeona Therapeutics Current Valuation Indicators
Abeona Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Abeona Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Abeona Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Abeona Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Abeona Therapeutics' worth.When determining whether Abeona Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Abeona Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abeona Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abeona Therapeutics Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abeona Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Abeona Stock, please use our How to Invest in Abeona Therapeutics guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abeona Therapeutics. If investors know Abeona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abeona Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Abeona Therapeutics is measured differently than its book value, which is the value of Abeona that is recorded on the company's balance sheet. Investors also form their own opinion of Abeona Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Abeona Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abeona Therapeutics' market value can be influenced by many factors that don't directly affect Abeona Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Abeona Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abeona Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abeona Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.